Skip to Main Content

Author Details

Sinja Taavitsainen
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
2018
19
14
PMIDPaper TitleJournal TitlePublished Year
37828555Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine.Genome Med2023
38023254Fanconi anemia pathway regulation by FANCI in prostate cancer.Front Oncol2023
35697807Estimation of tumor cell total mRNA expression in 15 cancer types predicts disease progression.Nat Biotechnol2022
33420073Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Nat Commun2021
33836265Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.Ann Oncol2021
34489465Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse.Nat Commun2021
34348967Subclone Eradication Analysis Identifies Targets for Enhanced Cancer Therapy and Reveals L1 Retrotransposition as a Dynamic Source of Cancer Heterogeneity.Cancer Res2021
34337548Combined Longitudinal Clinical and Autopsy Phenomic Assessment in Lethal Metastatic Prostate Cancer: Recommendations for Advancing Precision Medicine.Eur Urol Open Sci2021
34283056Chromatin and Epigenetic Dysregulation of Prostate Cancer Development, Progression, and Therapeutic Response.Cancers (Basel)2021
34083234Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.Clin Cancer Res2021
32451180Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.Eur Urol2020
31744831Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer.Clin Cancer Res2020
33033260Prostate cancer evolution from multilineage primary to single lineage metastases with implications for liquid biopsy.Nat Commun2020
32574722HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.Ann Oncol2020
32914020Evaluation of Commercial Circulating Tumor DNA Test in Metastatic Prostate Cancer.JCO Precis Oncol2019
31727538Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.Lancet Oncol2019
29367197Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.Cancer Discov2018
30272002Frequent mutation of the <i>FOXA1</i> untranslated region in prostate cancer.Commun Biol2018
29985419Interleukin 10 mutant zebrafish have an enhanced interferon gamma response and improved survival against a Mycobacterium marinum infection.Sci Rep2018
  • 1 - 19 of 19

Recommended Authors

Ontario Institute for Cancer Research
Career Start Year 2017
Number of shared co-authors 3
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 11
Erasmus MC Cancer Institute
Career Start Year 2017
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2017
Number of shared co-authors 4
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 3
Erasmus MC Cancer Institute
Career Start Year 2015
Number of shared co-authors 3
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 5
Ontario Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 4
University of California los angeles
Career Start Year 2015
Number of shared co-authors 5
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 2
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 11
Oncology R&D
Career Start Year 2013
Number of shared co-authors 1
Bluestar Genomics Inc.
Career Start Year 2010
Number of shared co-authors 10
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 6
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 5
University of Trento
Career Start Year 2009
Number of shared co-authors 7
The Institute of Cancer Research
Career Start Year 2008
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2007
Number of shared co-authors 9
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2007
Number of shared co-authors 3
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 3
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 14
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 1
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 9
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 13
Fred Hutchinson Cancer Center, University of Washington
Career Start Year 2002
Number of shared co-authors 14
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 7
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 10
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 4
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 16
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Career Start Year 1997
Number of shared co-authors 15

Collaborators

Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 15
University of British Columbia
Co-authored papers 10
University of British Columbia
Co-authored papers 10
University of British Columbia
Co-authored papers 10
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 5
University of British Columbia
Co-authored papers 5
Peter MacCallum Cancer Centre
Co-authored papers 3
Manchester Cancer Research Centre, University of Manchester
Co-authored papers 3
University of British Columbia
Co-authored papers 3
Northwestern University Feinberg School of Medicine Chicago
Co-authored papers 3
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Co-authored papers 3
University of British Columbia
Co-authored papers 3
the University of Texas MD Anderson Cancer Center
Co-authored papers 2
The Brady Urological Institute, The Johns Hopkins School of Medicine
Co-authored papers 2
Institute for Cancer Research, Oslo University Hospital
Co-authored papers 2
Ghent University, GZA Ziekenhuizen
Co-authored papers 2
University of British Columbia
Co-authored papers 2
University of Oxford
Co-authored papers 2
The Francis Crick Institute
Co-authored papers 2
University of British Columbia
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Agricultural Genomics Institute at Shenzhen, Chinese Academy of Agricultural Sciences
Co-authored papers 1
University of British Columbia
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
VIB-KU Leuven Center for Cancer Biology
Co-authored papers 1
University of Montreal Health Center
Co-authored papers 1
The Francis Crick Institute
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1